Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 38.50p 37.00p 40.00p 38.50p 38.50p 38.50p 103,559 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.6 -0.2 -4.3 - 2.14

Aortech Share Discussion Threads

Showing 5076 to 5099 of 5100 messages
Chat Pages: 204  203  202  201  200  199  198  197  196  195  194  193  Older
DateSubjectAuthorDiscuss
23/5/2018
01:38
I think some of the small scale odd-lot selling is people selling at 37p odd to buy/take up their open offer entitlements. Can't understand that myself, this is such a good deal that people who understand the story would be putting new money to work. Each to their own I guess.
the stigologist
22/5/2018
22:43
Lots of big claims made about this Company on this board but does anyone know how many customers are asking Biomerics specifically for Elast-Eon™ material. I mean are sales rising consistently. "The revenues generated by its licensing model cover the Company's current corporate costs.". Shouldn't these revenues more than cover the corporate costs next year? Fils
fillspectre
22/5/2018
22:30
Yes. Anyway looking forward to the double top on this chart :-D
the stigologist
22/5/2018
21:35
The Stig - true. Increasing liquidity to 14m shares is a start but only that.I hope Stockdale pick up a few decent placees in this round.
bones
22/5/2018
21:26
I suspect the CEO has bigger fish to fry than retail PIs to be honest. Should be courting smart money Institutions who invest in the small/mid cap world and will provide the supportive shareholder base from which Company can continue to build for the future.
the stigologist
22/5/2018
21:19
Coolhandfluke, your question needs to be directed at Bill Brown. Why don't you email him now that the intentions have been made public? Hopefully he would put you right about the balance of reward to be earned by the tie ups with the development cos. There's an AGM later in the summer too. Ask about it there.The EMI option clause meaning that 30% won't vest until £3 a share tells me plenty. None of these directors is on much of a salary either. £120k pa for the main CEO is pretty thin gruel even in the microcap world.
bones
22/5/2018
21:09
By the way my very good mate just happens to be a Cardiac specialist who regularly consults to EW and others. He is the one who described one of the new NEDs as 'a legend'. If AorTech deliver they will have no trouble gaining 'mindshare' with multi-billion dollar companies.
the stigologist
22/5/2018
20:58
Good spot bones I pity the fool who thinks 300p (Mkt Cap c.£50m) is the sum total of the ambitions here £100 per share is the all-time high (i.e. would be a £1.4bn market cap) For anyone who thinks that is 'absurd' MDT Medtronic Mkt Cap $115bn ABT Abbot Labs (St Judes Medical) Mkt Cap $106bn BSX Boston Scientific Mkt Cap $41bn EW Edwards Lifesciences Mkt Cap $29bn
the stigologist
22/5/2018
19:58
I don't see the excitement for the future of Aortech. I see the partnerships making money, providing services, for as long as AOR can afford to pay. All companies sight the value of the markets they operate in, penetrating it is another matter. I hope I'm wrong but if the price ever gets back to my buy in price of 55p I will be out.
coolhandfluke
22/5/2018
19:29
Interesting clause in the directors' EMI options explanations: (e) Vesting of Options As regards options to be granted to any Director, such options will vest as to - 20 per cent. after the expiry of 3 years from the date of grant, - 30 per cent. on the receipt by the Company of a CE Mark for any of its products and - 30 per cent. on the closing middle market quotation of the Ordinary Shares, as derived from AIM Appendix to the Daily Official List of the London Stock Exchange, being at least £3.00, being 10 times the Issue Price, for 10 consecutive days on which trading takes place on AIM. Wishful thinking on the last 30% part?
bones
22/5/2018
18:50
Brainless as ever...coolhand
k1ngkonggb
22/5/2018
18:47
Coolhand, that makes even less sense than post 4486. Running from what?
bones
22/5/2018
18:40
You got to know when to hold Know when to fold Know when to walk away Know when to run I think it's time to run.
coolhandfluke
22/5/2018
18:07
Six months to deliver a strategic plan, which has coincided with a cash call. The wave of optimism I am reading overwhelms me. If it takes this long to come up with a bucket full of promises, exactly how long & how many cash calls to implement them.
cocker
22/5/2018
16:10
Davisc5, more a case of the MMs waiting on the weak hands to fold...
bones
22/5/2018
14:01
It's like waiting for a bus
davisc5
22/5/2018
09:22
One more suggestion: I always try to introduce myself to the Co secretary and/or the CFO at an early opportunity and tell them that I would be interested in participating in any future fund raising, especially if the shares were to qualify for EIS, I then suggest that perhaps I could take a allocation in the so called subscription shares which are often issued alongside the placing shares. That has worked a couple of times for me in the past.
timbo003
22/5/2018
09:14
Getting EIS3 certificates through cheap and cheerful retail broker accounts is always a challenge, basically if you are paying just £10 or thereabouts to buy and sell the shares, you will get a quality of service to match. If you have the contact details for the CFO (or company secretary) that is always helpful, as you can make them aware of your participation in the open offer and they can ensure your details get submitted on the EIS1 form which goes off to HMRC.
timbo003
22/5/2018
08:10
Excellent point Harrogate. I can't imagine.
bearfoot
22/5/2018
08:07
But how will they get the certificates done for everyone in nominee accounts etc - Practically it sounds very very difficult
harrogate
22/5/2018
08:00
Harrogate - my belief is that the company doesn't need to know about (and is not responsible for) the eligibility of subscribers. It is only concerned with the eligibility of the Company itself. I had always understood it is the responsibility of the subscribers to ensure they personally and individually qualify for EIS, assuming they intend to claim relief for it through an EIS3 submission. On this basis I now reckon the Offer shares ARE eligible for EIS from the Company perspective BUT NOT from a subscriber basis (UNLESS the subscriber no longer holds shares at the time of the open offer issue). Having said all this understanding the constantly-changing EIS rules is one of the dark arts!
bearfoot
22/5/2018
07:15
Bearfoot - are you sure that the open offer shares are EIS - The RNS only mentions that the placing and subscription shares are - I am not sure how they could issue EIS certificates to open offer people to be honest as they would know nothing about their eligibility??
harrogate
22/5/2018
04:16
Timbo003->> interesting - thank you.
bearfoot
22/5/2018
00:59
Financial journalists are clueless about stocks. Either that or they've been asked to talk it down On Aim, shares in heart valve manufacturer Aortech International crashed after it tapped up investors for up to £2.6million to fund the development of new textile patches and grafts. Shares plunged 12.5 per cent, or 5.5p, to 38.5p. Read more: http://www.thisismoney.co.uk/money/markets/article-5754833/MARKET-REPORT-Ocado-soars-founder-18m.html#ixzz5GBXVgHRT
the stigologist
Chat Pages: 204  203  202  201  200  199  198  197  196  195  194  193  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180523 03:37:35